TheEdgeResearch
Home / Stocks / NEO

NeoGenomics, Inc. (NEO)

NASDAQ Healthcare Medical - Diagnostics & Research
$14.82 ▼ -1.79%
Market Cap
$1.93B
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Beta
1.83
52-Wk Range
7.07-20.15
CEO
Anthony Zook
Country
US
Currency
USD

NeoGenomics, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Fort Myers, FL, US. The stock last traded at $14.82, down 1.79% on the session, giving a market capitalisation of $1.93B. On trailing twelve-month figures it carries a trailing P/E of -60.05, a net margin of -4.1%. Its beta of 1.83 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-60.05
Price / Sales
2.45
Price / Book
2.38
EV / EBITDA
69.40
Gross margin
43.8%
Operating margin
-6.0%
Net margin
-4.1%
Return on equity
—
Debt / equity
0.56
Current ratio
3.53
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
2,500
IPO date
2004-03-16
Headquarters
Fort Myers, FL, US
About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.

Comparable companies

NeoGenomics, Inc. is most often compared with the following Healthcare names:

BDSXCSTLFRNMGHGRALMYGNPSNLVCYTWGSXGN
More research on NEO
NEO technical analysis NEO TheEdge Score Compare against peers
Open full interactive analysis & DCF →